This presentation (the "Presentation") is for informational purposes only and do not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, debt or other financial instruments of Canndoc Ltd. ("Canndoc") or InterCure Ltd. ("InterCure"). The information contained herein does not purport to be all-inclusive. The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any projections, modeling or any other information contained herein. Any person at any time acquiring securities must do so only on the basis of such person's own judgment as to the merits or the suitability of the securities for its purpose and only based on such information as is contained in such public filings, after having taken all such professional or other advice as it considers necessary or appropriate in the circumstances and not in reliance on the information contained in the Presentation. Canndoc and InterCure assume no obligation to update the information in this Presentation. Neither Canndoc nor InterCure accepts any liability whatsoever for any losses arising from the use of this Presentation or reliance on the information contained herein. Nothing herein shall be deemed to constitute investment, legal, tax, financial, accounting or other advice. Historical facts and past operating results are not intended to mean that future performances or results for any period will necessarily match or exceed those of any prior year.

This Presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation are forward-looking statements within the meaning of the Israeli Securities Law, 1968. Such forward looking statements with respect to strategies, prospects and other aspects of the businesses of Canndoc are based on current expectations that are subject to risks and uncertainties. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by the forward-looking statements, including without limitation, changes in the regulation and climate, the impact of the COVID-19 pandemic and changes in the market conditions. The forward-looking statements are made as of this date and Canndoc or InterCure do not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

LEGAL DISCLAIMER

OUR MISSION

Leading the global Pharma grade cannabis industry through our commitment to quality, innovation and improving lives.

CANNDOC IN NUMBERS

5 Operating territories and establishing partnerships in key target markes

10 IMCA approved advanced clinical trials

13 Years of experience and unique knowhow

40+ Thousands of patients treated with CANNDOC'S medical cannabis products over the years

32 Tones of GMP medical cannabis products under long term agreements

100 100% of the Authorized Pharmacies in Israel selling CANNDOC'S GMP products

100+ Scalable International supply chain for 100+ Tons of high quality GMP production

140 / 85 / 31% MKT CAP 140M\$ [TASE:INCR] Capital 85M\$ EBITDA 31% + POSITIVE CF

Global Cannabis Market

Pharma grade (GMP)

Medical/recreational

Source: Market research companies

Southern Site (Cultivation)

CANNDOC'S Cultivation sites

Total of 1,700,000 square feet Max capacity of 88 tons Fully operational 300,000 square feet

Northern Site (Cultivation and R&D)

CANNDOC'S Cultivation sites

Total of 55,000 (expansion option: 160,000) square feet

Max capacity of 3 tons

Fully operational 55,000 square feet

aphria" E ORGANIGRAM &TILRAY

t.ookies

Global supply partners

DAIMOND, CANADA NEW BRUNSWICK, CANADA CANTANHEDE, PORTUGAL

Total of 1,300,000 square feet

Max capacity of 140 tons annually

Total of 560,000 square feet

Max capacity of 70 tons annually

Total of 350,00 square feet

Max capacity of 25 tons annually

Highly Scalable Supply Model

‣ ‣ ‣ Ability to significantly scale up cultivation operations without capital investment

-

‣ ‣ Established global footprint representing ~1B\$ of cultivation facility investment

‣ Intercontinental supply chain for consistent and highest quality branded products for all addressable markets

We Believe In Trusted Brands

Who will capture increased growth?

Brands

Licensed producers

COUCBOM INCREA THC20/CEDA INCICA

CANBOCES

10g ====

ATILRAY

10g Park Party

Paving The Way for the Regulations

First Israeli LP to become a public company

First Israeli company to import medical grade cannabis into Israel

First to receive export approval to Europe

Export & Import Leaders

GIVOL - the leading cannabis pharmacy chain

Clinical Trials & R&D partners

CANNDOC'S Clinical Trials Pipeline

Planned Clinical - Pipeline

‣ Double-blind, randomized, placebo-controlled (1:1) ; Full spectrum derived cannabis oil

Change in median monthly seizure frequency over study period compared
Treatment-emergent adverse events and serious adverse events (SAEs) during treatment

Phase of Development	Indication	Number of Patients	Primary Endpoint(s)
2a	Adult Epilepsy	52	- Change in median monthly seizure frequency over study period compared to 2-month baseline period
2a	CINV related to Breast Cancer Treatment	72	- SAEs during treatment
2a	Parkinson's Disease	60	- SAEs during treatment - Change in The Parkinson's Disease Questionnaire
2a	Diabetic Neuropathy	44	- Neuropathic Pain Diagnostic Questionnaire score (scale 4-10)
2a	Fibromyalgia	62	- Safety and tolerability of the product based on AEs during treatment - To determine the effect of the product on Fibromyalgia Impact Questionnaire
2a	Rheumatoid Arthritis	64	- To determine the effect of the product on ACR20
2a	Radicular Pain	36	-Safety of the product

Safety and tolerability of the product based on AEs during treatment - To determine the effect of the product on Fibromyalgia Impact Questionnaire - To determine the effect of the product on Physician Global Impression of Change
Safety and tolerability of the product based on Adverse Events during treatment - To determine the effect of the product on ACR20

CANNDOC'S Clinical Trials Pipeline

Planned Clinical - Pipeline

‣ Double-blind, randomized, placebo-controlled (1:1) ; Full spectrum derived cannabis oil

Characterize the effects of medicinal cannabis in different THC:CBD ratios on associated morbidity on the Autistic spectrum To examine the influence of cannabis treatment on cognitive and adjacent capabilities Test the levels of THC and CBD in children treated with cannabis

Primary Endpoint(s)	Number of Patients	Indication	Phase of Development
on the Autistic spectrum	75	Pediatric/Young Adult Autism	3
Lumbar Radiculopathy	50	Lumbar Radiculopathy	2a
- Safety rate of AEs - Improvement in Pittsburgh sleep quality index-addendum (PSQI-A) score	50	Post-Traumatic Stress Disorder	2a *

-Safety and tolerability of the product based on AEs during treatment -To evaluate the pain-relieving effect of CD-008 sublingual drops, in addition to standard of care, on

Safety rate of AEs - Improvement in Insomnia Severity Index Score - Improvement in Pittsburgh sleep quality index-addendum (PSQI-A) score ⁵⁰ Post-Traumatic Stress

* Pending IMCA approval

• Cash of 48 million NIS

SUMMERY Q3 2020 MEDICAL CANNABIS SEGMENT

Record revenue of 22.5 million NIS, solid demand for CANNDOC'S quality products • Accelerated growth of X8 to last year and X2 of previous quarter • 7th consecutive quarter GP improvement to more than 50% • Operating profit of 6.1 million NIS (27% of turnover) • Positive EBITDA of 7.0 million NIS (31%)
•Positive cash flow from operating activities of 6.3 million NIS